A5031390636- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Childhood Cancer Survivors' Quality of Life
- Renal Transplantation Outcomes and Treatments
- Acute Myeloid Leukemia Research
- T-cell and B-cell Immunology
- Immune Cell Function and Interaction
- Chronic Myeloid Leukemia Treatments
- Cancer survivorship and care
- Mesenchymal stem cell research
- Chronic Lymphocytic Leukemia Research
- Polyomavirus and related diseases
- Palliative Care and End-of-Life Issues
- Transplantation: Methods and Outcomes
- Systemic Sclerosis and Related Diseases
- Family Support in Illness
- Neutropenia and Cancer Infections
- Multiple Myeloma Research and Treatments
- Immunotherapy and Immune Responses
- Cytomegalovirus and herpesvirus research
- Corneal Surgery and Treatments
- Eosinophilic Disorders and Syndromes
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Hedgehog Signaling Pathway Studies
Fred Hutch Cancer Center
2016-2025
University of Washington Medical Center
2016-2025
University of Washington
2016-2025
Medical College of Wisconsin
2016-2025
Johns Hopkins University
2001-2025
New York Psychoanalytic Society and Institute
2025
Jackson Health System
2021-2025
University of Miami
2021-2025
Bayer (Germany)
2024-2025
National Marrow Donor Program
2013-2024
The 2005 National Institutes of Health (NIH) Consensus Conference proposed new criteria for diagnosing and scoring the severity chronic graft-versus-host disease (GVHD). 2014 NIH consensus maintains framework prior with further refinement based on evidence. Revisions have been made to address areas controversy or confusion, such as overlap GVHD subcategory distinction between active past tissue damage. Diagnostic involvement mouth, eyes, genitalia, lungs revised. Categories should be defined...
This consensus document is intended to serve 3 functions. First, it standardizes the criteria for diagnosis of chronic graft-versus-host disease (GVHD). Second, proposes a new clinical scoring system (0-3) that describes extent and severity GVHD each organ or site at any given time, taking functional impact into account. Third, guidelines global assessment are based on number organs sites involved degree involvement in affected (mild, moderate, severe). Diagnosis requires presence least 1...
Bortezomib, a boronic acid dipeptide, is novel proteasome inhibitor that has been shown in preclinical and phase 1 studies to have antimyeloma activity.In this multicenter, open-label, nonrandomized, 2 trial, we enrolled 202 patients with relapsed myeloma was refractory the therapy they had received most recently. Patients 1.3 mg of bortezomib per square meter body-surface area twice weekly for weeks, followed by week without treatment, up eight cycles (24 weeks). In suboptimal response,...
The JAK2V617F allele has recently been identified in patients with polycythemia vera (PV), essential thrombocytosis (ET), and myelofibrosis myeloid metaplasia (MF). Subsequent analysis shown that constitutive activation of the JAK-STAT signal transduction pathway is an important pathogenetic event these patients, enzymatic inhibition may be therapeutic benefit this context. However, a significant proportion ET or MF are JAK2V617F-negative. We hypothesized might also occur as consequence...
Randomized trials have shown that the transplantation of filgrastim-mobilized peripheral-blood stem cells from HLA-identical siblings accelerates engraftment but increases risks acute and chronic graft-versus-host disease (GVHD), as compared with bone marrow. Some studies also are associated a decreased rate relapse improved survival among recipients high-risk leukemia.
Genetic mutations drive the pathogenesis of myelodysplastic syndrome (MDS) and are closely associated with clinical phenotype. Therefore, genetic may predict outcomes after allogeneic hematopoietic stem-cell transplantation.We performed targeted mutational analysis on samples obtained before transplantation from 1514 patients MDS who were enrolled in Center for International Blood Marrow Transplant Research Repository between 2005 2014. We evaluated association outcomes, including overall...
The lack of standardized criteria for quantitative measurement therapeutic response in clinical trials poses a major obstacle the development new agents chronic graft-versus-host disease (GVHD). This consensus document was developed to address several objectives be used GVHD-related trials. proposed measures should practical use both by transplantation and nontransplantation medical providers, adaptable adults children, focused on most important GVHD manifestations. also give preference...
This consensus document provides an update for pathologists and clinicians about the interpretation of biopsy results use this information in management hematopoietic cell transplantation patients. Optimal sampling tissue preparation are discussed. Minimal criteria diagnosis graft-versus-host disease (GVHD) proposed, together with specific requirements chronic GVHD. Four final diagnostic categories (no GVHD, possible consistent definite GVHD) reflect integration histopathology clinical,...
Anemia resulting from cancer, or its treatment, is an important clinical problem increasingly treated with the recombinant hematopoietic growth factor erythropoietin. To address uncertainties regarding indications and efficacy, American Society of Clinical Oncology Hematology developed evidence-based practice guideline for use epoetin in patients cancer. The panel found good evidence to recommend as a treatment option chemotherapy-associated anemia hemoglobin level less than 10 g/dL. Use...
Although transplant practices have changed over the last decades, no information is available on trends in incidence and outcome of chronic graft-versus-host disease (cGVHD) time. This study used central database Center for International Blood Marrow Transplant Research (CIBMTR) to describe time cGVHD incidence, nonrelapse mortality, risk factors cGVHD. The 12-year period was divided into 3 intervals, 1995 1999, 2000 2003, 2004 2007, included 26,563 patients with acute leukemia, myeloid...
Several international recommendations address the assessment of graft-versus-host disease (GvHD) after hematopoietic cell transplantation (HCT). This position statement by GvHD experts from European Society for Blood and Marrow Transplantation (EBMT), National Institutes Health (NIH) Center International Transplant Research (CIBMTR) reviews existing guidelines both acute chronic GvHD, addresses potential confusions that arise in daily practice proposes consensus definitions many key terms....
In 2005, the National Institutes of Health (NIH) Chronic Graft-versus-Host Disease (GVHD) Consensus Response Criteria Working Group recommended several measures to document serial evaluations chronic GVHD organ involvement. Provisional definitions complete response, partial and progression were proposed for each overall outcome. Based on publications over last 9 years, 2014 has updated its recommendations interpretation responses. Major changes include elimination clinical parameters from...